About Avifavir

 

Avifavir (Favipiravir) is the first oral drug approved to treat coronavirus infection. It is also the first favipiravir-based drug in the world approved for the treatment of COVID-19. The Russian Ministry of Health included Avifavir in the seventh edition of its guidelines for prevention, diagnosis and treatment of new coronavirus infection COVID-19. Avifavir has already been delivered to over 200,000 patients in Russia and 16 other countries in Latin America, Middle East, Central and Southern Asia.

 

Favipiravir-based drugs have demonstrated efficacy in three independent clinical trials held in leading medical centers across Russia, involving 700 patients with confirmed cases of COVID-19. The drug disrupts the reproduction mechanisms of the coronavirus, relieving symptoms and
halving the treatment period compared to standard therapy.

  • - According to the results of the 10 days of the clinical trials, Avifavir demonstrated safety
    with no new or previously unreported side effects detected;
  • - Median elimination of the virus took four days compared to nine days with standard
    therapy, according to the study;
  • - Efficacy of the drug is above 80%, a criterion for a drug with high antiviral activity;
  • - Following the first four days of treatment, 65% of the 40 patients who took Avifavir
    tested negative for coronavirus, which is twice as many as in the standard therapy group. By day 10, the number of patients whose tests returned negative results reached 90%;
  • - The body temperature of 68% of patients taking Avifavir returned to normal earlier (on
    the third day) than in the control group (on the sixth day);

The Russian Ministry of Health has included Avifavir in the list of nationally
recommended drugs for treatment of COVID-19.


Press releases

Moscow, March 26, 2020 - The supervisory board of the Russian Direct Investment Fund (RDIF)
approved the creation of a joint venture (JV) with the ChemRar Group of Companies for the
production of favipiravir and other innovative antiviral drugs, including those based on it, for
the treatment of coronavirus infection.

Moscow, May 21, 2020 - The Ministry of Health of the Russian Federation approved the launch
of the final stage, which will involve 330 patients compared to 60 during the initial stage, as
well as additional research and medical centers. In total, 30 medical centers in nine Russian
regions will conduct studies at the final stage. RDIF and ChemRar have applied to the Russian Ministry of Health for the accelerated registration of Favipiravir in accordance with Russian Government’s Decree No. 441 of 3 April 2020.

Moscow, May 22, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group today announce the start of the final stage of the multicenter randomized open comparative clinical trial of the drug Favipiravir on patients hospitalized with COVID-19.

Moscow, July 2, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group produced the first 100,000 courses of the Russian coronavirus drug Avifavir in June, significantly exceeding initially planned production levels of 60,000 courses.

Moscow, July 14, 2020 - Chromis, a joint venture established by the Russian Direct Investment
Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, announce the signing of
license and collaboration agreement with Brazil’s Axis BioTec to deliver the first Russian anti-
COVID drug Avifavir to Brazil.

Moscow, August 03, 2020 - Chromis, a joint venture established by the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, announce the signing of a distribution agreement with South Africa’s 3Sixty Biopharmaceuticals, a subsidiary of 3Sixty Global Solutions Group, to deliver Avifavir, the first Russian anti-COVID drug, to South Africa.

Moscow, August 03, 2020 - Chromis, a joint venture established by the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, announce the signing of an exclusive agreement with Bolivia’s Sigma Corp S.R.L. (Industria Quimico Farmaceutica Sigma Corp S.R.L.) to deliver the first Russian anti-COVID drug Avifavir to Argentina, Bolivia, Equador, El Salvador, Honduras, Paraguay and Uruguay.

 


Publications/media
Bloomberg
Bloomberg
CNBC
Reuters
Sputniknews
Wall Street Journal